These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36265750)

  • 21. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience.
    Isaac M; Mireskandari K; Fallaha N; Ospina LH; Javidi E; Chorfi S; Superstein R; Hamel P; Tehrani NN
    Can J Ophthalmol; 2023 Dec; 58(6):553-558. PubMed ID: 35940211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection.
    Lu X; Zeng X; Chen M; Fan Z; Zheng L; Tian Y; Zhang S; He JC; Zhang G
    Graefes Arch Clin Exp Ophthalmol; 2022 Oct; 260(10):3213-3219. PubMed ID: 35546637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
    Chow SC; Lam PY; Lam WC; Fung NSK
    Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity.
    Gundlach BS; Kokhanov A; Altendahl M; Suh SY; Fung S; Demer J; Pineles S; Khitri M; Chu A; Tsui I
    Am J Ophthalmol; 2022 Jun; 238():86-96. PubMed ID: 34788594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Br J Ophthalmol; 2019 Sep; 103(9):1332-1336. PubMed ID: 30514709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.